IPO Issue Details
Issue Price / Price Band₹111 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,200 Shares per Lot
Total Issue Size54,03,600 shares (aggregating up to ₹59.98 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformBSE SME
IPO TypeSME
Subscription OpenWed, 05 Feb 2025
Subscription CloseFri, 07 Feb 2025
Anchor AllotmentTue, 04 Feb 2025
Basis of AllotmentMon, 10 Feb 2025
Initiation of RefundsTue, 11 Feb 2025
Credit of Shares to DematTue, 11 Feb 2025
Listing DateWed, 12 Feb 2025
UPI Mandate Deadline2025-02-07
Application & Investment Details
Retail — Min (1 Lots)133200 — 1200 shares
Retail — Max (13 Lots)₹1,731,600 (13 Lots)
HNI — Min (2 Lots)266400 — 2400 shares
EPS (Pre-IPO)₹8.04
EPS (Post-IPO)₹6.52
P/E Ratio (Pre-IPO)13.81x
P/E Ratio (Post-IPO)17.04x
Net Offer to Public51,32,400 shares (aggregating up to ₹56.97 Cr)
Reserved for Market Maker2,71,200 shares (aggregating up to ₹3.01 Cr)
Pre-IPO Promoter Holding1,56,00,000 shares
Post-IPO Promoter Holding2,00,03,600 shares
Fresh Issue Shares41,32,400 shares (aggregating up to ₹45.87 Cr)
Offer for Sale Shares10,00,000 shares of ₹10 (aggregating up to ₹11.10 Cr)
About Amwill Health Care Ltd.
Incorporated in August 2017, Amwill Health Care Limited is a derma-cosmetic development firm that collaborates with contract manufacturers, distributors, and third-party product development agencies. This collaboration has enhanced the company's manufacturing, packaging, and distribution capabilities.The product portfolio of the Company is divided into two categories, namely,Development of generic dermatological solutions andFormulating targeted solutions for dermatological issues.The company markets its products in Karnataka, Andhra Pradesh, and Telangana, focusing on strengthening its presence before entering new markets to build a customer base.The company develops products for dermatological disorders, including acne, fungal infections, anti-aging, histaminic, periorbital hyperpigmentation, scabies, perspiration, trichology, and vitiligo.As of September 30, 2024, the company has 84 employees on payroll.Competitive StrengthExtensive product portfolio supported by product formulation capabilitiesProvision of high-quality product development through tie-ups with contract manufacturers and prototype developersWell-experienced management team with proven project management and implementation skillsAsset-light business model.
Objects of the Issue
Amwill Health Care Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
Funding of working capital requirements of the Company
2
Marketing and brand-building activities
3
General corporate purposes
Shareholding & Lock-in
Pre-IPO Promoter Holding
1,56,00,000 shares
Post-IPO Promoter Holding
2,00,03,600 shares